Cancidas (previously Caspofungin MSD) 유럽 연합 - 체코어 - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika pro systémové použití - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Combivir 유럽 연합 - 체코어 - EMA (European Medicines Agency)

combivir

viiv healthcare bv - lamivudin, zidovudin - hiv infekce - antivirotika pro systémové použití - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Descovy 유럽 연합 - 체코어 - EMA (European Medicines Agency)

descovy

gilead sciences ireland uc - emtricitabin, tenofovir alafenamide - hiv infekce - antivirotika pro systémové použití - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

Fampyra 유럽 연합 - 체코어 - EMA (European Medicines Agency)

fampyra

biogen netherlands b.v.  - fampridin - roztroušená skleróza - další léky na nervový systém - přípravek fampyra je indikován pro zlepšení chůze u dospělých pacientů s roztroušenou sklerózou s pohybovými postižení (il2ra 4-7).

Hetlioz 유럽 연합 - 체코어 - EMA (European Medicines Agency)

hetlioz

vanda pharmaceuticals netherlands b.v. - tasimelteon - poruchy spánku, cirkadiánní rytmus - psycholeptika - přípravek hetlioz je indikován k léčbě non-24 hodinové poruchy spánku (non-24) u úplně slepých dospělých.

Bravecto 유럽 연합 - 체코어 - EMA (European Medicines Agency)

bravecto

intervet international b.v - flouraner - ektoparazitika pro systémové použití, isoxazolines - dogs; cats - psi:- léčba napadení klíšťaty a blechami;produkt může být použit jako součást léčebné strategie alergické dermatitidy vyvolané blechami (fad). - k léčbě demodikóza způsobená demodex canis;- při léčbě sarkoptového svrabu (sarcoptes scabiei var.. canis) napadení. - for reduction of the risk of infection with babesia canis canis via transmission by dermacentor reticulatus. [chewable tablets only]cats:- for the treatment of tick and flea infestations;the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad). - pro léčbu infestace s ušními roztoči (otodectes cynotis).

Inlyta 유럽 연합 - 체코어 - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - karcinom, ledvinná buňka - inhibitory proteinkinázy - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Virbagen Omega 유럽 연합 - 체코어 - EMA (European Medicines Agency)

virbagen omega

virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.

Zolvix 유럽 연합 - 체코어 - EMA (European Medicines Agency)

zolvix

elanco gmbh - monepantel - anthelmintika, - ovce - perorální roztok zolvix je širokospektré anthelmintikum pro léčbu a kontrolu gastrointestinálních hlístic infekcí a souvisejících chorob u ovcí, včetně jehňat, hoggets, chovných beranů a bahnic. spectrum of activity includes fourth larvae and adults of: , haemonchus contortus*;, teladorsagia circumcincta*;, teladorsagia trifurcata*;, teladorsagia davtiani*;, trichostrongylus axei*;, trichostrongylus colubriformis;, trichostrongylus vitrinus;, cooperia curticei;, cooperia oncophora;, nematodirus battus;, nematodirus filicollis;, nematodirus spathiger;, chabertia ovina;, oesophagostomum venulosum. , * včetně inhibované larvy. veterinární léčivý přípravek je účinný proti kmenům těchto parazitů odolné vůči (pro)benzimidazoles, levamisol, morantel, makrocyklické laktony a h. contortus kmeny odolné vůči salicylanilidům.

Jinarc 유럽 연합 - 체코어 - EMA (European Medicines Agency)

jinarc

otsuka pharmaceutical netherlands b.v. - tolvaptan - polycystický ledvina, autosomální dominantní - diuretika, - přípravek jinarc je indikován ke zpomalení progrese vzniku cyst a renální insuficience autosomálně dominantní polycystická choroba ledvin (pchlad) u dospělých pacientů s ckd fáze 1 až 3 při zahájení léčby s důkazy o rychle postupující onemocnění,.